Bristol-Myers Squibb Company (BMY)
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.96, denoting a +1.85% move from the preceding trading day.
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
BMY's Breyanzi tops $1B run rate in 2025, expanding across five cancers with new FDA nod, strengthening its CAR T leadership despite rising competition.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $59.2, indicating a +2.65% shift from the previous trading day.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
The latest trading day saw Bristol Myers Squibb (BMY) settling at $60.65, representing a +1.54% change from its previous close.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
